Member Info for Quickdraw18

Lot of subsidiaries for a newly formed distributor imo

2002 - ZEUS CAPITAL LIMITED
June 19 - ZEUS GROUP LIMITED (Peter Whitehurst)
14th Floor, 82 King Street, Manchester, England, M2 4WQ

Xx/XX - PLW CONSULTING Ltd in (Peter Whitehurst)
Kemp House, 160 City Road, London, United Kingdom, EC1V 2NX

9/04 - AGILE LIFE SCIENCES LTD (PW) - Kemp House, 160 City Road, London, United Kingdom, EC1V 2NX

20/04 - MEDUSA 19 GROUP LIMITED _
(Mark Wright & Richard Hughes)
14th Floor 82 King Street, Manchester, England, M2 4WQ

22/04 - MEDUSA 19 LIMITED - (Mark Wright & Richard Hughes)
14th Floor, 82 King Street, Manchester, England, M2 4WQ

.30/04 - MEDUSA ASSET MANAGEMENT LIMITED (IR)
14th Floor, 82 King Street, Manchester, England, M2 4WQ

04/06 - SATURN GROUP HOLDINGS LIMITED - (IR)
82 Kinkg Street, Manchester, Lancashire, United Kingdom, M2 4WQ

05/06 - SATURN PASSPORT LIMITED (IR)
82 King Street, Manchester, Lancashire, United Kingdom, M2 4WQ

05/06 - SATURN ASSET MANAGEMENT LIMITED - (IR)
82 King Street, Manchester, Lancashire, United Kingdom, M2 4WQ

23/07 - MEDUSA 19 LIFE SCIENCES LTD -
(Peter Whitehurst)
Kemp House, 160 City Road, London, United Kingdom, EC1V 2NX

31/07 - SATURN PASS LIMITED (IH)
14th Floor, 82 King Street, Manchester, Lancashire, United Kingdom, M2 4WQh

17/08 - MEDUSA 19 - Sarah Irvine - Head of Customer Service/Delivery - emailed
20 Dale Street Manchester M1

Remember all you heard it from me first. Even interpreted it as a postive for avacta.

Still do. Innova 3.5m short term contact gives you the chance to get your new test validated abroad (not sure why you are doing this) and then clinically evaluated in EU and UK

I'd check out the tender. Here are the reg changes. Think i found from here.

PS Nova have a bit of skin in the LFT game via microgen, so i keep an in this stuff. Peace out all.

https://www.gov.uk/guidance/lateral-flow-validation-prioritisation-criteria-for-rapid-diagnostic-assays-for-specific-sars-cov-2-antigens

In all seriousness I'd have a look at this all. Think the LFT tender has been cancelled.

My take is because the requirements were updated on the 8th Feb its been pulled and hopefully will be reissued as per the week of 22nd feb that some of you have been posting about.

This is likely good news for avacta as AS said aiming to provide an update on test by end of March

https://www.find-tender.service.gov.uk/Notice/002876-2021?origin=SearchResults&p=1

Do Abingdon have 3 antigen tests in the works and if so who are they with?

PAH00 over been clear what my motivation is on here, ODX and Avacta. I'm not being subtle. Would never short a stock mind. Just calling it how I've researchesd it.

"i've been clear on the ODX board what my motives are. Is a tragedy for PI's to be selling Novacyt a company who have delivered 10 COVID products this yr to buy shares in ODX, or even worse Abingdon who have a failed antibody product in a failed market (1,100 anybody tests in UK, flat lined).

And is a shame for investors to be buying Abingdon on the back of what seems like Avacta's flawed Affimer LFT antigen and hopes and dreams resting on your new agreement

Especially on the back of the revised gov Antigen LFT guidelines issued on the 8th.

No shorting by me, no need to, awful way to make money. But am not above being a white night in dark armour. Sitting on a heap of tragic UK diagnostics news I've been quietly collating since August/September. There is another that shall remain nameless until i do some more research"

Doze, with a bit of luck the new Avacta, Mologic team up will work and you will get a 2 gene S&N LFT going in time before the big boys economies of scales take over and price avacta out of the market. As Avacta don't sound like this project has started yet a year into development time seems to be against them.
Roche and Abbott have capacity to make think it's 200m LFT's between them. That's what I mean by economies of scale.

There's still time, i see testing persisting for 3 years at decent levels. Prof Pea**** of Cambridge uni who is working with Novacyt (speaking at NovaChat on 26/02) said on bbc she sees sequencing lasting 10+ years. Expect we'll find out soon who's test she and Cambridge uni are backing

https://www.bbc.co.uk/news/uk-56019995

Only in two of those lol. Read my posts. Am up 124% this year, 800% in 6 yrs cheers for your concerns

Richnob why would i filter you?

My point about the £7m is on 2nd April raised £2m from BooHoo lads, £3.75m from punters 6th April

https://www.lse.co.uk/rns/AVCT/subscription-to-raise-1632-million-5cyiqn790x9b3rv.html

Then AS said no further raises. Then £45m 4th June
https://www.lse.co.uk/rns/AVCT/proposed-fundraising-to-raise-up-to-16345-million-cthleu71ydzk09y.html

Use of proceeds:

"Rapid Scale-up of Diagnostics Business, £10 million

Accelerated Expansion of Pipeline of Differentiated Cancer Therapies, £35 million"

Then 8th Oct 2m shares following the exercise of share options by a services provider of 10 pence each when price was around £1.80. No details other than service provider, not a bad deal for the service provider. I wondered at the time could this have been Cytiva payment?

https://www.lse.co.uk/rns/AVCT/issue-of-equity-ch37r62el4om4ah.html

He reinvested his performance related bonus is my understanding. So that's when he had the available funds.

PS no directors have sold Novacyt shares in part yr, only buys. They did ONE raise of £380k which returned £92m profit last yr.

Haven't had to raise £40m and then still pay supplier with was it £7m of stock?

You guys will know better, i just follow now and again

ES23 I'll for you https://www.investopedia.com/articles/financialcareers/07/warning_signs.asp

"Big Insider Selling
The smart money investors, meaning institutional and executive holders of the stock, typically dump their shares ahead of a bankruptcy filing or really difficult times. Be on the lookout for insider selling.

However, during the normal course of business, some insiders may sell the stock from time to time. Essentially, you should pay attention to unusually large or frequent transactions, particularly those that occur in or around the time negative news is released"

AS had the acumen to sell £500k at £1.80 and buy a house

Graham Mullis had the acumen to buy £497,000 Novacyt shares at £8.17 and not sold a bean. Sound investing and confidence booster

One man has delivered, one sorted himself out, missed targets and blamed others, even an airline and Brexit!

Just for you Timster https://twitter.com/DopeinkInvest/status/1360165851241005058?s=19

The Covid-19 Genomics UK Consortium is a network of public health bodies and labs and currently analyses more than 20,000 positive tests a week.

In recent weeks, it has been explained that about 5-10% of positive tests are selected randomly to be sent on for further genome analysis but the consortium says, as the number of cases falls below its capacity, its aim is to genetically screen every positive coronavirus test.

Prof Pea**** told Newscast that while it is normal to see variants, only a very small number have "special features". These can make them more transmissible, avoid the immune response and affect vaccination, or have the potential to cause more severe disease.

"These are the things we are looking out for. I'd say it happens vanishingly rarely but we have to be on the look out for it," the expert, who was previously director of the government's National Infection Service, said

To carry on my Bowie them if you follow me, we've got 10 years

https://www.bbc.co.uk/news/uk-56019995

Just a few hours, current sequencing takes 8 days.

Prof Pea**** of Cambridge uni says COVID genetic sequencing will persist for 10+ years

Prof Sharon Pea**** will be speaking at Novacyt's NovaTalk on 26th Feb https://twitter.com/gggg2120/status/1359589905513480198?s=19

For newer investors, potential investors and those with poor memories

"Collaboration with AstraZeneca, GSK and University of Cambridge to support UK national effort to increase COVID-19 testing"
https://novacyt.com/2020/04/08/collaboration-with-astrazeneca-gsk-and-university-of-cambridge-to-support-uk-national-effort-to-increase-covid-19-testing/

#Novacyt "SNPsig assays provide an alternative to next generation sequencing & S gene target failure (SGTF), enabling scientists to analyse & monitor relevant genomic mutations on site, within a matter of hours" #ALNOV #NCYT

https://www.primerdesign.co.uk/products-hub/snpsig-sars-cov-2-voc-identification-kits

"Are you Global in disguise...……" don't know that one?

ODX and Avacta, been there done that. Sold avacta at Alistair Smith levels for about 90% profit. Bought ODX at low 20's and sold for high 50's i think in September. No BS imo Novacyt with £277m sales and £92m in cash was a far more attractive and safer investment for me.
Of course takes sound vision to see ahead of the market

Alistair can't even see ahead of his own project plan.

In the summer time, BooHoo that date slipped, give me 20p I'll give you £2 ;-)

Cheers Karen and Prop5, have widened my focus recently too ;-) Hate seeing money after bad......
Let's all make money as Pi's, stuff bad tech, businesses and these ii's picking our pockets. Sometimes need to be cruel to be kind. Folk can asses my judgement at the end. If I'm wrong I'll take the bashing i would deserve. But I'm a cautious investor with stack of research, far to much to share at mo. Its starting to come out

mowzerrocks for your info PCR tests are qualitative so one can analyse the results accross the CT spectrum.

A LFT is a quantitative tests which is set at its set corresponding value. Seems the equivalence is CT of 25. Which is why LFT's can only detect the most infectious and miss those with early infections and will be entering their most infectious period in matter of days.

The other significant advantage of PCR is ability to
monitor viral mutations. LFT's won't be able to do this.

Alway a risk manufacturing large batches of LFT's which may not idendify mutations, especially if one targets only the S gene like some companies seem to have